NSGO-OV-UMB1; ENGOT-OV30 / NSGO: A Phase II Umbrella Trial in Patients With Relapsed Ovarian Cancer
Latest Information Update: 18 Sep 2023
At a glance
- Drugs Durvalumab (Primary) ; Oleclumab (Primary) ; Tavolimab (Primary) ; Tremelimumab (Primary)
- Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Therapeutic Use
- Acronyms Umbrella Trial
- 16 Jan 2022 This trial has been completed in Finland(End date:2021-12-31), according to European Clinical Trials Database record.
- 07 Jan 2022 Status changed from recruiting to completed.
- 20 Aug 2020 Planned primary completion date changed from 30 Mar 2020 to 30 Mar 2023.